Calcipotriene is a synthetic vitamin D analog. The effectiveness of topical calcipotriene in the treatment of psoriasis may result from inhibition of epidermal proliferation and stimulation of differentiation of epidermal cells. Also, calcipotriene increases the number of vitamin D receptors in epidermal nuclei. Acute toxicity has been reported as LD50 values as follows. Dog skin >1.5 mg/kg, rat skin >15 mg/kg and rat subcutaneous 2.19 mg/kg.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
The OEL/ADE monograph for Calcipotriene is under development.
You can contact us and let us know if you'd like to be notified when this document becomes available.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.